Page 144 - CW E-Magazine (9-4-2024)

Pharmaceuticals Hydrocarbons

DISTRIBUTION PARTNERSHIP COST ESCALATION
Sanofi and Cipla partner to expand reach of CNS Chennai refi nery expansion cost goes up over Rs. 3,600-crore

portfolio in India Indian Oil Corporation (IOC) has said ing, IOC said its board at a recent meeting and balance 50% to be held by fi nancial/
it will raise its stake in the joint venture accorded approval for the revision in cost strategic/public investors. Thereafter, the
Sanofi India Ltd. (SIL) and Sanofi Frisium, a leading anti-epileptic medi- reach programmes to expand access to building a 9-mtpa refi nery at Chennai to of the project from Rs. 29,361-crore to joint venture, Cauvery Basin Refi nery and
Healthcare India Pvt. Ltd. and Cipla cation. While Sanofi India will continue these treatments for patients. 75% after the cost to the project escalated Rs. 33,023-crore, representing an increase Petrochemicals Ltd. (CBRPL), was incor-
Ltd. have announced an exclusive part- to own, import, and manufacture its by over 12%. The company however did of Rs. 3,662-crore or 12.5%. porated on January 6, 2023.
nership for distribution and promotion complete range of CNS products across “Central Nervous System is one of not give reasons for the cost escalation.
of Sanofi India’s Central Nervous Sys- plants in India and internationally, the most challenging areas in medicine, IOC’s board had on January 29, 2021 IOC had planned to pull down the
tem (CNS) product range in India. As Cipla will leverage its capabilities and and we believe this partnership is a signi- Originally, IOC and its subsidiary, approved the implementation of a 9-mtpa 1-mtpa Nagapattinam refi nery of CPCL
a part of this partnership, Cipla will robust India-wide network of strong fi cant step forward to address unmet Chennai Petroleum Corporation Ltd. refi nery in the Cauvery Basin at Naga- and build the brand new 9-mtpa unit.
be responsible for the distribution of marketing and sales professionals, distri- needs of patients,” said Mr. Achin (CPCL), were to hold a 25% stake in the pattinam by CPCL at an estimated cost The unit was to come up in 48 months.
Sanofi India’s six CNS brands including butors, institutions, and market out- Gupta, CEO – One India Business, Cipla. joint venture that was to build a new unit of Rs. 29,361-crore, to meet the demand National Iranian Oil Co. (NIOC), which
adjacent to the existing refi nery of CPCL of petroleum products in southern India. holds a 15.4% stake in CPCL (IOC holds
CANCER TREATMENT at Nagapattinam (Tamil Nadu). The re- Alongside, approval was also given for the 51.89%), is not a partner in the new pro-
AstraZeneca India bags dual CDSCO nod maining 50% equity was to come from formation of a joint venture between IOC ject, largely due to the constraints on in-
and CPCL with equity holding of 50% vestments posed by US sanctions on Iran.
fi nancial investors. In a stock exchange fi l-
for Trastuzumab deruxtecan ELECTRIFICATION INFRASTRUCTURE

AstraZeneca Pharma India Ltd. has breast cancer, and locally advanced low in India, but is gradually rising Zetwerk bags order from IOC to set up over 1,400 EV
received permission from the Central or metastatic gastric cancer: The drug with almost a 40% increase in cases,
Drugs Standard Control Organisation was earlier approved by DCGI for the over the past 25 years. Gastric cancer, fast chargers
(CDSCO), Directorate General of treatment of adult patients with unre- on the other hand, is the sixth most
Health Services, Government of India, sectable or metastatic HER2-positive prevalent cancer in India affecting Bangalore-based contract manufac- said it has bagged the largest order sustainable future,” Zetwerk Business Head –
for import and sale of Trastuzumab breast cancer who have received a men, and poses a considerable chal- turing services provider, Zetwerk, has amongst all the suppliers from IOC. Renewables, Mr. Abhay Adya said.
deruxtecan lyophilised powder for prior anti-HER2-based regimen. lenge with a fi ve-year survival rate of said it has bagged an order from Indian “These charging stations will be de- Under the contract, Zetwerk will set
two additional indications. The new less than 7% for those diagnosed at an Oil Corporation (IOC) to set up over ployed as per requirement across IOC up 1,400-plus EV chargers with a capa-
indications are HER2-low metastatic The incidence of breast cancer is advanced stage. 1,400 fast chargers for electric vehicles outlets, providing a seamless charging city of 50-60 kW and 100-120 kW. These
(EVs) across the country.
experience. By conveniently locating will be the DC dual gun CCS2 DC
Ipca Labs inks technology transfer deal with Omexa IOC had fl oated a tender for 6,000 these stations in major cities, we will chargers that can charge two vehicles
Formulary for anti-cancer biosimilar chargers, in which 40 EV suppliers enable the widespread adoption of EV simultaneously with a dynamic load-
across the country participated. Zetwerk mobility and drive the nation towards a sharing mode, the statement said.

Ipca Laboratories has entered into Omexa Formulary, an innovation driven will also help Ipca in the development PRICE FIXING
a technology transfer agreement with and fast-growing biotech company, and delivery of affordable and quality Govt. revises price of domestic natural gas to $9.87
Chennai-based Omexa Formulary for a shall facilitate Omexa to build a solid biologic medication for the treatment
biosimilar clone, process development foundation for potential anti-cancer and of chronic illnesses in the global market – from April 1
and knowledge transfer for the global anti-infl ammatory monoclonal antibody a presently unmet and crucial clinical
market. Under this agreement, lpca will product development. This collaboration need”. The Ministry of Petroleum and Natural national gas prices, an offi cial notifi cation for use in automobiles, piped to household
grant to Omexa a non-exclusive right Gas has lowered the prices of natural gas said. However, the price of gas used for kitchens for cooking and used to generate
to research, develop, manufacture and Zydus Lifesciences gets four observations extracted from various fi elds. Gas from making CNG for fuelling automobiles or electricity and make fertilisers. Two dif-
market an anti-cancer biosimilar. Omexa diffi cult areas like deepwater, ultra-deep- piping to household kitchens for cooking ferent formulas govern rates paid for gas
will develop the biosimilar from early for Gujarat facility water, and high-pressure, high-tempera- purposes will remain unchanged due to a produced from legacy or old fi elds of
stage of development to clinical trials ture (HPTP) fi elds now costs $9.87 per price cap set at 30% less than market rates national oil companies like Oil and Natural
and subsequent commercial launch. Zydus Lifesciences said the USFDA 2024. While the inspection closed with million British thermal unit (mmBtu), such as that paid to Reliance. This is the Gas Corporation (ONGC) and Oil India
has issued a Form-483 with four obser- four observations, there were no data down from $9.96 per mmBtu. These re- third straight bi-annual reduction in rates Ltd. (OIL), and for newer fi elds lying in
Commenting on the deal, Mr. Pranay vations, following the inspection of its integrity-related observations, it said. vised rates will be effective from April 1 for diffi cult fi elds. The government bi-an- diffi cult-to-tap areas, such as deep-sea.
Godha, Managing Director and CEO, Ahmedabad-based SEZ Onco Injectable “Zydus will closely work with the USF- to September 30, 2024. The cut in prices is nually fi xes prices of the locally-produced Rates are fi xed on April 1 and October 1
lpca Labs, said “This collaboration with manufacturing plant from March 18-27, DA to address the observations,” it added. in line with softening of benchmark inter- natural gas, which is converted into CNG each year.

144 Chemical Weekly April 9, 2024 Chemical Weekly April 9, 2024 145

Contents Index to Advertisers Index to Products Advertised